Variation patterns of two degradation enzyme systems in articular cartilage in different stages of osteoarthritis: Regulation by dehydroepiandrosterone

Clinica Chimica Acta

Volumn 408, Issue 1-2, 2009, Pages 1-7

  Bao, Jia peng ^a,b   Chen, Wei ping ^a,b   Feng, Jie ^a,b   Zhao, Jie ^a,b   Shi, Zhong li ^a,b   Huang, Kai ^a,b   Wu, Li dong ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Second Hospital   (China)

Author keywords

Cathepsins; Cystatin C; Dehydroepiandrosterone; Osteoarthritis; Plasminogen activator inhibitor 1; Urokinase plasminogen activator

Indexed keywords

CATHEPSIN; CYSTATIN C; CYSTEINE PROTEINASE; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRASTERONE; UROKINASE;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CRUCIATE LIGAMENT INJURY; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE MATRIX; CONTROLLED STUDY; DEGENERATIVE DISEASE; GENE EXPRESSION; HISTOLOGY; JOINT DESTRUCTION; MALE; MORPHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOARTHRITIS; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTERIOR CRUCIATE LIGAMENT; CARTILAGE, ARTICULAR; CYSTATINS; CYSTEINE PROTEASES; DEHYDROEPIANDROSTERONE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; MALE; OSTEOARTHRITIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RABBITS; RNA, MESSENGER; TIME FACTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

ORYCTOLAGUS CUNICULUS;

EID: 69849087207     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.06.040     Document Type: Article

References (55)

1. Lark M.W., Bayne E.K., Flanagan J., et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Investig 100 (1997) 93-106
2. Poole A.R. An introduction to the pathophysiology of osteoarthritis. Front Biosci 4 (1999) D662-670
3. Dean D.D., Martel-Pelletier J., Pelletier J.P., Howell D.S., and Woessner Jr. J.F. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Investig 84 (1989) 678-685
4. Tortorella M.D., Malfait A.M., Deccico C., and Arner E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis and cartilage/OARS, Osteoarthrit Res Soc 9 (2001) 539-552
5. Lang A., Horler D., and Baici A. The relative importance of cysteine peptidases in osteoarthritis. J Rheumatol 27 (2000) 1970-1979
6. Brommer E.J., Dooijewaard G., Dijkmans B.A., and Breedveld F.C. Plasminogen activators in synovial fluid and plasma from patients with arthritis. Ann Rheum Dis 51 (1992) 965-968
7. Jin T., Tarkowski A., Carmeliet P., and Bokarewa M. Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis. Arthrit Res Ther 5 (2003) R9-R17
8. Chapman H.A., Riese R.J., and Shi G.P. Emerging roles for cysteine proteases in human biology. Ann Revi Physiol 59 (1997) 63-88
9. Keyszer G., Redlich A., Haupl T., et al. Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis: a parallel investigation by semiquantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. Arthrit Rheumat 41 (1998) 1378-1387
10. Wang D., Li W., Pechar M., Kopeckova P., Bromme D., and Kopecek J. Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis. Int J Pharmaceut 277 (2004) 73-79
11. Appleton C.T., Pitelka V., Henry J., and Beier F. Global analyses of gene expression in early experimental osteoarthritis. Arthrit Rrheumat 56 (2007) 1854-1868
12. Konttinen Y.T., Mandelin J., Li T.F., et al. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthrit Rheumat 46 (2002) 953-960
13. Hou W.S., Li Z., Buttner F.H., Bartnik E., and Bromme D. Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation. Biol Chem 384 (2003) 891-897
14. Dejica V.M., Mort J.S., Laverty S., et al. Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage. The American journal of pathology 173 (2008) 161-169
15. Baici A., Horler D., Lang A., Merlin C., and Kissling R. Cathepsin B in osteoarthritis: zonal variation of enzyme activity in human femoral head cartilage. Ann Rheum Dis 54 (1995) 281-288
16. Berardi S., Lang A., Kostoulas G., Horler D., Vilei E.M., and Baici A. Alternative messenger RNA splicing and enzyme forms of cathepsin B in human osteoarthritic cartilage and cultured chondrocytes. Arthr Rrheumat 44 (2001) 1819-1831
17. Maciewicz R.A., Wotton S.F., Etherington D.J., and Duance V.C. Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L. FEBS Letters 269 (1990) 189-193
18. Petanceska S., Canoll P., and Devi L.A. Expression of rat cathepsin S in phagocytic cells. The J Biol Chem 271 (1996) 4403-4409
19. Abrahamson M., Olafsson I., Palsdottir A., et al. Structure and expression of the human cystatin C gene. Biochem J 268 (1990) 287-294
20. Martel-Pelletier J., Cloutier J.M., and Pelletier J.P. Cathepsin B and cysteine protease inhibitors in human osteoarthritis. J Orthop Res 8 (1990) 336-344
21. Ronday H.K., Smits H.H., Van Muijen G.N., et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 35 (1996) 416-423
22. Hilal G., Martel-Pelletier J., Pelletier J.P., Duval N., and Lajeunesse D. Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts. Arthr Rheumat 42 (1999) 2112-2122
23. Baker E.A., and Leaper D.J. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer 39 (2003) 981-988
24. Chu S.C., Yang S.F., Lue K.H., Hsieh Y.S., Hsiao T.Y., and Lu K.H. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee. J Rheumatol 33 (2006) 311-317
25. Jo H., Park J.S., Kim E.M., et al. The in vitro effects of dehydroepiandrosterone on human osteoarthritic chondrocytes. Osteoarthr Cartil/OARS, Osteoarthr Res Soc 11 (2003) 585-594
26. Jo H., Ahn H.J., Kim E.M., et al. Effects of dehydroepiandrosterone on articular cartilage during the development of osteoarthritis. Arthr Rheum 50 (2004) 2531-2538
27. Wu L.D., Yu H.C., Xiong Y., and Feng J. Effect of dehydroepiandrosterone on cartilage and synovium of knee joints with osteoarthritis in rabbits. Rheumatol Int 27 (2006) 79-85
28. Yoshioka M., Shimizu C., Harwood F.L., Coutts R.D., and Amiel D. The effects of hyaluronan during the development of osteoarthritis. Osteoarthr Cartil/OARS, Osteoarthr Res Soc 5 (1997) 251-260
29. Pritzker K.P., Gay S., Jimenez S.A., et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthr Cartil/OARS, Osteoarthr Res Soc 14 (2006) 13-29
30. Morko J.P., Soderstrom M., Saamanen A.M., Salminen H.J., and Vuorio E.I. Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis. Ann Rheum Dis 63 (2004) 649-655
31. Baici A., Lang A., Horler D., Kissling R., and Merlin C. Cathepsin B in osteoarthritis: cytochemical and histochemical analysis of human femoral head cartilage. Ann Rheum Dis 54 (1995) 289-297
32. Mehraban F., Tindal M.H., Proffitt M.M., and Moskowitz R.W. Temporal pattern of cysteine endopeptidase (cathepsin B) expression in cartilage and synovium from rabbit knees with experimental osteoarthritis: gene expression in chondrocytes in response to interleukin-1 and matrix depletion. Ann Rheum Dis 56 (1997) 108-115
33. Belcher C., Fawthrop F., Bunning R., and Doherty M. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Ann Rheum dis 55 (1996) 230-236
34. Fairbairn S., Gilbert R., Ojakian G., Schwimmer R., and Quigley J.P. The extracellular matrix of normal chick embryo fibroblasts: its effect on transformed chick fibroblasts and its proteolytic degradation by the transformants. J Cell Biol 101 (1985) 1790-1798
35. Knudsen B.S., Harpel P.C., and Nachman R.L. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Investig 80 (1987) 1082-1089
36. Martel-Pelletier J., Faure M.P., McCollum R., Mineau F., Cloutier J.M., and Pelletier J.P. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. J Rheumatol 18 (1991) 1863-1871
37. Sun J.S., Wu C.X., Tsuang Y.H., Chen L.T., and Sheu S.Y. The in vitro effects of dehydroepiandrosterone on chondrocyte metabolism. Osteoarthritis Cartil/OARS, Osteoarthr Res Soc 14 (2006) 238-249
38. Pelletier J.P., Mineau F., Fernandes J., Kiansa K., Ranger P., and Martel-Pelletier J. Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts. Clin Exp Rheumatol 15 (1997) 393-398
39. Chu S.C., Yang S.F., Lue K.H., Hsieh Y.S., Li T.J., and Lu K.H. Naproxen, meloxicam and methylprednisolone inhibit urokinase plasminogen activator and inhibitor and gelatinases expression during the early stage of osteoarthritis. Clin Chim Acta 387 (2008) 90-96
40. Nonaka T., Kikuchi H., Ikeda T., Okamoto Y., Hamanishi C., and Tanaka S. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis. J Rheumatol 27 (2000) 997-1004
41. Hsieh Y.S., Yang S.F., Lue K.H., Chu S.C., and Lu K.H. Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis. J Orthop Res 26 (2008) 475-484
42. Kawaida R., Ohtsuka T., Okutsu J., et al. Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL. J Exp Med 197 (2003) 1029-1035
43. Sloane B.F., Yan S., Podgorski I., et al. Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. Seminars Cancer Biol 15 (2005) 149-157
44. Judge A.R., Koncarevic A., Hunter R.B., Liou H.C., Jackman R.W., and Kandarian S.C. Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy. Am J Physiol 292 (2007) C372-382
45. Jean D., Guillaume N., and Frade R. Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity. Biochem J 361 (2002) 173-184
46. Shi G.P., Webb A.C., Foster K.E., et al. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J Biol Chem 269 (1994) 11530-11536
47. Kamolmatyakul S., Chen W., Yang S., et al. IL-1alpha stimulates cathepsin K expression in osteoclasts via the tyrosine kinase-NF-kappaB pathway. J Dental Res 83 (2004) 791-796
48. Ruettger A., Schueler S., Mollenhauer J.A., and Wiederanders B. Cathepsins B, K, and L are regulated by a defined collagen type II peptide via activation of classical protein kinase C and p38 MAP kinase in articular chondrocytes. J Biol Chem 283 (2008) 1043-1051
49. Hsieh Y.S., Yang S.F., Lue K.H., Chu S.C., Li T.J., and Lu K.H. Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis. J Rheumatol 34 (2007) 785-793
50. Yang J.Y., Schwartz A., and Henderson E.E. Inhibition of HIV-1 latency reactivation by dehydroepiandrosterone (DHEA) and an analog of DHEA. AIDS Res Hum Retrovir 9 (1993) 747-754
51. Poynter M.E., and Daynes R.A. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273 (1998) 32833-32841
52. Dashtaki R., Whorton A.R., Murphy T.M., Chitano P., Reed W., and Kennedy T.P. Dehydroepiandrosterone and analogs inhibit DNA binding of AP-1 and airway smooth muscle proliferation. J Pharmacol Exp Therap 285 (1998) 876-883
53. Yoshimata T., Yoneyama A., Jin-no Y., Tamai N., and Kamiya Y. Effects of dehydroepiandrosterone on mitogen-activated protein kinase in human aortic smooth muscle cells. Life Sci 65 (1999) 431-440
54. Lin S.Y., Cui H., Yusta B., and Belsham D.D. IGF-I signaling prevents dehydroepiandrosterone (DHEA)-induced apoptosis in hypothalamic neurons. Mol Cell Endocrinol 214 (2004) 127-135
55. Jiang Y., Miyazaki T., Honda A., et al. Apoptosis and inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway in the anti-proliferative actions of dehydroepiandrosterone. J Gastroenterol 40 (2005) 490-497